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Backgrounds: Pseudoprogression disease (PsPD) is commonly observed during glioblastoma (GBM) follow-up after
adjuvant therapy. Because it is difficult to differentiate PsPD from true early progression of GBM, we have used a
quantitative proteomics strategy to identify molecular signatures and develop predictive markers of PsPD.
Results: An initial screening of three PsPD and three GBM patients was performed, and from which 530 proteins
with significant fold changes were identified. By conducting biological functional analysis of these proteins, we
found evidence that the protein synthesis network and the cellular growth and proliferation network were most
significantly affected. Moreover, six of the proteins (HNRNPK, ELAVL1, CDH2, FBLN1, CALU and FGB) involved in the
two networks were validated (n = 18) in the same six samples and in twelve additional samples using
immunohistochemistry methods and the western blot analysis. The receiver operating characteristic (ROC) curve
analysis in distinguishing PsPD patients from GBM patients yielded an area under curve (AUC) value of 0.90 (95%
confidence interval (CI), 0.662-0.9880) for CDH2 and.0.92 (95% CI, 0.696-0.995) for CDH2 combined with ELAVL1.
Conclusions: The results of the present study both revealed the biological signatures of PsPD from a proteomics
perspective and indicated that CDH2 alone or combined with ELAVL1 could be potential biomarkers with high
accuracy in the diagnosis of PsPD.
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Glioblastoma (GBM) is one of the most malignant brain
tumors. After the postoperative use of radiotherapy for
GBM became common, a phenomenon termed pseudo-
progression disease (PsPD) was identified [1,2]. With the
widely implementation of the Stupp protocol for treating
GBM, this phenomenon has been inceasingly reported,
with an incidence rate varies among reports (5.5%-64%)
[3-6]. PsPD is often misdiagnosed as tumor recurrence
and misleads the clinical treatment. However, little is
known about why PsPD occurs in a subset of GBM pa-
tients and the fundamental biological features of PsPD
remain unclear [5,7-10].* Correspondence: sunwei1018@hotmail.com; zlw.tth@hotmail.com
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unless otherwise stated.From a diagnostic perspective, no single imaging
technique, including T1-weighted magnetic resonance
imaging (MRI), magnetic resonance spectroscopy
(MRS), relative cerebral blood volume (rCBV)-based para-
metric response mapping and 18fluorodeoxyglucose (18 F-
FDG)-positron emission computed tomography (PET), has
been adequate for differentiating PsPD from true early tumor
progression with high sensitivity and specificity [4,5,11-16].
Moreover, molecular biological studies have failed to uncover
biomarkers linked to PsPD for clinical use. Although a
multitude of genetic and molecular changes involved
in GBM, including O6-methylguanine–DNA methyl-
transferase (MGMT) promoter methylation, isocitrate
dehydrogenase 1 (IDH1) mutation, p53 mutation and Ki-67
expression, have been found to be associated with PsPD, the
predictive value of these biomarkers remains debatable
[5,8,17-19]. Therefore, except for cases of pathological verifi-
cation, PsPD is still predominantly diagnosed retrospectively.
Thus, there is an urgent need for the exploration of more re-
liable biochemical markers that can accurately identify PsPD.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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information and several proteomic studies of gliomas have
been recently reported [20,21], which demonstrated a pos-
sibility to investigate this phenomenon by using proteo-
mics methods. Herein, this present study was designed to
identify biological signatures and explore biomarkers for
PsPD using differential proteomic techniques (Figure 1).
Results
Identification of proteins with significant fold changes in
PsPD versus GBM
In this iTRAQ-labeling proteomic study, by comparing
the total proteomes of tissue from PsPDs with the pro-
teomes of tissues from GBMs, we identified 4048 pro-
teins in PsPD and 3846 proteins in GBM (Additional file 1:
File s1, Additional file 2: File s2, Additional file 3: File s3
and Additional file 4: File s4). To measure the quantitative
correlation between pairwise sample combinations within
each group, a Pearson’s correlation coefficient (ranged from
0.967 to 0.980) was calculated and showed high biological
reproducibility (Additional file 5: Figure s1). To maintain a
low false-positive rate of comparative analysis between theFigure 1 Workflow of the iTRAQ proteomic strategy. In this work, three
GBM were used for iTRAQ labeled proteomic analysis. The proteins identifie
functions analysis. Several candidate proteins with interesting biological fun
same samples used for proteomic analysis as well as additional samples.groups, an average CV of 0.37 (Additional file 5: Figure s2)
was employed to filter out data with poor linearity, corre-
sponding to coverage of more than 80% of the 3390 quanti-
fied proteins both in PsPDs and GBMs. Next, a threshold
of ≥2-fold and p < 0.05 was taken to identify 530 proteins
with significant fold changes for further analysis (Figure 2).
Among these proteins, 57 proteins were up-regulated and
473 were down-regulated in PsPD compared with GBMs
(Additional file 6: File s5 and Additional file 7: File s6).
Interaction networks and functional pathway analysis
Functional pathway analysis was performed for the 530
proteins to better understand the biological features of
PsPD. Gene ontology analysis indicated broad distribu-
tion of these proteins, with the most frequently repre-
sented categories being cellular compartment, molecular
function, and biological processes (Figure 3). The results
of Ingenuity Pathway Analysis (IPA) analysis indicated
that the protein synthesis network and the cellular growth
and proliferation network were mostly affected (Figure 4),
with a series of cellular functions being significantly inhibited
in PsPD compared with GBM (Additional file 5: Figure s3).pathologically verified tissue samples of PsPD and three samples of
d were quantitatively analyzed using Panther and IPA for biological
ctions were selected and further validated using IHC and WB of the
Figure 2 Volcano plots of identified proteins in PsPD vs GBM.
The x-axis of the graph refers to the log transformation of fold
change, whereas the y-axis of the graph refers to the negative log
transformation of the p-value.
Figure 3 Panther analysis of PsPD vs N-GBM. Graph A shows cellular co
Graph C shows biological process analysis.
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(z-score:-2.886) abilities of tumor cells were significantly
downregulated in PsPD compared with GBM. More-
over, the translation (z-score: −2.464), synthesis of protein
(z-score: −2.236) and metabolism of protein (z-score:-
2.046) were also significantly downregulated in PsPD com-
pared with GBM.
Selection of candidate proteins for validation
Three candidate proteins (HNRNPK, ELAVL1 and CDH2)
involved in the two networks and acting as key-point
proteins were selected out. In order to explore more prom-
ising biomarkers, all secreted proteins with more than 2
fold changes (Additional file 8: File s7) were searched
against the protein atlas database (http://www.proteinatlas.
org), because the protein atlas database provided thempartment analysis; Graph B shows molecular function analysis; and
Figure 4 Cellular growth and proliferation network and protein synthesis network from IPA analysis. Graph A shows the protein synthesis
focused network, and Graph B illustratescellular growth and proliferation focused function network. Proteins in red were up-regulated in PsPD
compared with N-GBM, and proteins in green were down-regulated in PsPD compared with N-GBM. Proteins pointed by the blue arrow were the
selected out candidate proteins used for analysis and further validation.
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and related antibodies. Proteins with median or high
positive expression in glial cell or tissue were chosen for
further functional analysis. Three proteins (FBLN1, CALU
and FGB) meeting the criteria were selected out. The
results of IHC and WB validation of the six proteins
were in accordance with the proteomic findings (Figures 5,
6). Moreover, a quantitative analysis of the WB results was
performed (Table 1, Figure 6). As shown in the figure,
statistically significant differences were found between the
groups.Evaluation of HNRNPK, ELAVL1, CDH2 and FBLN1 as
diagnostic markers for PsPD
The WB analysis revealed that HNRNPK, ELAVL1,
CDH2 and FBLN1 were of statistical significance and
exihibited obvious fold changes between PsPDs and
GBMs (Table 1). Furthermore, the area under the ROC
curves for ELAVL1, HNRNPK, CDH2 and FBLN1 were
0.86 (p = 0.013), 0.75 (p = 0.077), 0.90 (p = 0.006) and
0.66 (p = 0.258), respectively (Figure 7, Additional file 9:
Table S1). A pairwise comparison of ROC curves shows
no statistical difference between these four proteins
Figure 5 Results of immunohistochemical analysis of CDH2, ELAVL1, HNRNPK, FBLN1, CALU and FGB in tissue samples. Magnification:
200X. Representative images of paraffin-embedded sections of PsPD and GBM tissue that were HE stained and immunostained for CDH2,ELAVL1,
HNRNPK, FBLN1, CALU and FGB. Graph A shows the validation of these six candidate proteins in the six samples used for proteomic analysis. The
first three columns show the validation results in N-GBMs and the second three columns show the results in the PsPDs. Graph B shows the
validation in an additional twelve samples. The first four column shows the validation results in additionally selected N-GBMs, the second four
column shows the results in R-GBMs, and the third four column shows the results in PsPDs. * indicates the twelve additionally selected samples.
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the combined ROC curve for CDH2 and ELAVL1 was
0.92 (P = 0.003), indicating that the diagnostic value of
CDH2 alone or combined with ELAVL1 was improved.
Discussion
By using iTRAQ-labeled proteomic analysis and con-
ducting further biological functional analysis of fold-
changed proteins, we identified the biological features of
PsPD from the perspective of proteomics and explored
several candidate proteins to be predictive biomarkers.
Protein metabolism and upstream regulatory mechanisms
play fundamental roles
The results of the biological analysis revealed the protein
synthesis network to be broadly affected. Based on the
data from the present study, the expression level of pro-
teins involved in protein synthesis and upstream regula-
tory mechanisms, such as RNA post-transcriptional
modification, post-translational modification and protein
folding are significantly different between PsPDs andGBMs (Figure 4, Additional file 5: Figure s3, Additional
file 7: File s5 and Additional file 8: File s6), indicating these
mechanisms may be significantly affected. Two candidate
proteins, HNRNPK and ELAVL1, involved in the protein
synthesis network were selected and validated.
HnRNPs comprise a large family of proteins with ap-
proximately 30 members that share some structural do-
mains. Previous studies have shown that hnRNPs played
central roles in several cellular functions, among which
HNRNPK was found to play an essential role in cellular
proliferation by regulating protein synthesis and is over-
expressed in head and neck tumors [22,23]. In recent
studies, HNRNPK was also found to play a significant
role in the mechanism of DNA damage-related cell cycle
arrest under ionizing conditions [24,25], which is similar
to the effect of radiotherapy. In the present study,
hnRNPs (HNRNPC, HNRNPK, HNRNPM and HNRNP)
were found to play roles in the protein synthesis network
and were down-regulated in PsPDs compared with GBMs,
which may reflect the effect of chemo-radiotherapy treat-
ment in GBM patients.
Figure 6 Western blot analysis for ELAVL1, HNRNPK, CDH2 and FBLN1 in tissue samples. Graph A shows that high levels of ELAVL1,
HNRNPK, CDH2 and low levels FBLN1 were detected in N-GBMs compared with PsPDs in the six samples for proteomic analysis. Graph B shows
the quantification of expression levels using densitometry. Graph C shows that high levels of ELAVL1, HNRNPK, CDH2 and low levels of FBLN1
were detected in GBMs (both N-GBM and R-GBM) compared with PsPDs in additional twelve samples. Graph D shows the quantification of ex-
pression levels using densitometry. * indicates the twelve additionally selected samples;** p < 0.05.
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protein, ELAVL1, was selected. Under hypoxia, ELAVL1
plays a significant role in the regulation of angiogenesis
by stabilizing vascular endothelial growth factor A
(VEGF-A) mRNA [26,27]. VEGF-A is one of the major






vs N-GBM)FC (PsPD vs N-GBM) P value
HNRNPK P61978 0.34 ** down-regul
ELAVL1 B4DVB8 0.23 ** down-regul
FBLN1 P23142 2.74 ** up-regulatio
CDH2 P19022 0.29 0.05 down-regul
CALU O43852 0.33 0.15 down-regul
FGB P02675 16.06 ** up-regulatio
Note: The 1st column refers to the candidate proteins used for validation; the 2nd c
proteins; the 3rd column refers to the results of iTRAQ labeled quantitative analysis
expression levels of these candidate proteins in the immunohistochemistry (IHC) an
the 4 candidate proteins, ELAVL1, HNRNPK, CDH2 and FBLN1, #indicates the results[28]. Both VEGF and ELAVL1 were identified down-
regulated in PsPD compared with GBM, suggesting the
possibility of angiogenesis inhibition in PsPD. This result
may also help explain how hypoxia is involved in the for-
mation of PsPD, as has been proposed in several studies
[18,29].WB Quantitative Analysis
PsPD vs N-GBM (MS) PsPD vs N-GBM# PsPD vs R-GBM#
ation 0.82 0.26 0.14*
ation 0.46* 0.33 0.21*
n 1.19 1.63* 1.43
ation 0.1* 0.35 0.4
ation No Validation No Validation No Validation
n No Validation No Validation No Validation
olumn refers to the corresponding accession number of these candidate
, FC, fold change, **p < 0.01; The 4th column refers to the differential
alysis; The 5th column refers to the results of the western blot validation of
in additional samples, *p < 0.05.
Figure 7 Roc curve of predictive biomarkers. The ROC curve of CDH2, ELAVL1 and the combination of these two candidate proteins was
shown in the graph with different lines.
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Many researchers have proposed that PsPD occurs due
to the induction of cell death by radiotherapy and/or
chemotherapy of malignant glioma [17,30]. These find-
ings indicate a hypothesis that an underlying relationship
between PsPD occurrence and cell death induction by
adjuvant therapy may exist [30]. In this present study,
the results of biological analysis shows that most of the
proteins related to the cellular growth and proliferation
functions as well as the invasion and proliferation abil-
ities of tumor cells were down-regulated (Figure 4,
Additional file 5: Figure s3, Additional file 6: File s5 and
Additional file 7: File s6), demonstrating these functions
may have been significantly inhibited. Except for
HNRNPK and ELAVL1, another two candidate proteins,
CDH2 and CALU, involved in the network of cellular
growth and proliferation were selected and validated.
A previous study on brainstem glioma showed that
higher expression of CDH2 predicts the progression of
malignant tumors and tends to predict a shorter survival
time of patients [31]. Other studies also indicated CDH2
may be functionally correlated with tumorigenesis in gli-
oma cells and involved in mediating glioma cell migration
[32-34]. In the present study, CDH2 is involved in several
cellular functions (Additional file 5: Figure S3, Additional
file 9: Table S3) and found to be down-regulated in PsPDs
compared with GBMs (Table 1, Figure 4). The results werein accordance with previous studies and may demonstrate
the malignancy changes in PsPD.
Another protein CALU, is a calcium-binding protein
located in the endothelium that is involved in protein
folding and sorting. This protein was recently found to
be highly expressed in normal neural stem cells and
GBM stem-like cells compared with the GBM tumor tis-
sue [35]. Additionally, the gene CALU was also observed
to be up-regulated in GBM but not in low-grade astro-
cytoma or oligodendroglioma [36]. These results indi-
cated that the expression levels of CALU may be
correlated with tumor cell proliferation ability, which is
in accordance with the biological analysis results of this
present study.
Validation of secretory proteins as candidate biomarkers
At present, there are no suitable specific biomarkers that
can be used to accurately differentiate PsPDs from GBMs.
Secretory proteins have the potential to be detected as bio-
markers in body fluids. Therefore, we also selected three
candidate secretory proteins, CALU (described above),
FGB and FBLN1, for validation. The validation results
were in accordance with the proteomic findings. It is note-
worthy that, previous studies have reported that FBLN1
expression is elevated in breast tumors [37] and ovarian
cancer cells [38]. But no details about the roles of FBLN1
in gliomas have been reported previously.
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validation results both identified that the expression
level of HNRNPK, ELAVL1, CDH2 and FBLN1 in PsPDs
were significantly different from GBMs (Figures 5, 6).
ROC curves yielded an AUC value of 0.90 (95% CI,
0.662-0.9880) for CDH2 and.0.92 (95% CI, 0.696-0.995)
for CDH2 combined with ELAVL1, which indicated that
these two proteins could be potential biomarkers with
relatively high accuracy in the diagnosis of PsPD.
Conclusion
In summary, our work offers an initial description of the
proteins conserved in PsPDs and GBMs as well as novel
information on proteins that are differentially expressed
between groups. Through biological analysis and valid-
ation of the proteomic findings, this present study not
only revealed the molecular signatures but also provide
novel markers that may help to identify the mechanisms
behind and allow the diagnosis of PsPD. However, due
to the low number of samples used in the present study,
above conclusions were just preliminary results, there-
fore, it should be careful to use our conclusions. Further
verification in additional samples should be helpful and
essential to understand the process.
Materials and methods
Sample collection and pathological examination
A set of fresh frozen tissue samples that included PsPD
(n = 3) and newly diagnosed GBM (N-GBM, n = 3) was
obtained under an Institutional Review Board-approved
protocol at the Beijing Tiantan Hospital of Capital Med-
ical University. Consents of clinical data and samples
used for the study have been obtained from the patients
and their families. PsPD was diagnosed according to the
criteria of Macdonald [39] without viable tumor recur-
rence by pathological verification. The tissue samples
were snap-frozen immediately after resection and stored
at −80°C. To ensure that the fragments used for prote-
omic analysis contained a sufficient proportion (at least
80%) of the target tissue, we evaluated each specimen
before use. Moreover, twelve additional samples were se-
lected for verification by IHC and WB, including four
PsPD, four N-GBM and four recurrent GBM (R-GBM)
tissue samples (Additional file 9: Table S4).
ITRAQ sample preparation
First, 80 mg samples from each of the six frozen tissue
samples selected for the proteomics screening were
rinsed with PBS, and each sample was then mixed with
lysis buffer (50 mMTris-HCl, 2.5 M thiourea, 8 M urea,
4% CHAPS, 65 mM DTT) for total protein extraction.
The total protein concentration of each sample was de-
termined using the Bio-Rad RC DC Protein Assay.The proteins from each sample were pooled equally ac-
cording to the total amount of protein and digested by
filter-aided sample preparation combined with a microwave-
assisted protein preparation method as previously described
[40,41]. The peptides were dried by vacuum centrifugation
and stored at −80°C.
The digested PsPD and GBM samples were mixed
equally to create the internal standard and labeled by
114 iTRAQ. The three PsPD samples and the three
GBM samples, were individually labeled with 115, 116
or 117 iTRAQ according to the manufacturer’s protocol
(ABsciex).
2D-LC and MS/MS conditions
For offline separation a HPLC from Waters was used, and
for online LC/MS/MS analysis a nano-ACQUITYUPLC sys-
tem from Waters was used. First, the pooled mixture of the
labeled samples was fractionated using a high-pH RPLC col-
umn from Waters (4.6 mm×250 mm, C18, 3 μm). For each
fraction the injection volume was 8uL. The samples were
loaded onto the column in buffer A1 (1‰ aqueous ammonia
in water, pH= 10), and eluted by buffer B1 (1‰ aqueous am-
monia in 10% water and 90%ACN; pH= 10, flow rate =
1 mL/min) with the gradient of 5–90%for 60 min. The eluted
peptides were collected at a rate of one fraction per minute,
and pooled into 20 samples. Each sample was analyzed by
LC-MS/MS using an RP C18 self-packing capillary LC col-
umn (75 μm×100 mm, 3 μm) and a Triple TOF 5600 mass
spectrometer. For Triple TOF 5600 a nano source was used.
The MS data were acquired in high sensitivity mode with de-
tailed parameters for Triple TOF 5600 being set as following:
ion spray voltage was 2200v, curtain gas was 25, gas 1 was 5,
gas 2 was 0, temperature was 150, declustering potential was
100, mass range was 350–1250 for MS and 100–1800 for
MS/MS, collision energy was 35, and the resolution of MS
and MS/MS was 40000 and 20000. An elution gradient of
5–30% buffer B2 (0.1% formic acid, 99.9% ACN; flow rate,
0.3 μL/min) for 50 min was used for the analysis. Thirty
data-dependent MS/MS scans were acquired for every full
scan. The normalized collision energy used was 35%, and
charge state screening (including precursors with +2 to +4
charge state) and dynamic exclusion (exclusion duration of
15 s) were performed. Analyst TF 1.6 was used to control
the instruments.
Database search
The MS/MS spectra were searched against the human
subset of the Uniprot database (84910 entries) (http://
www.uniprot.org/) using the Mascot software version
2.3.02 (Matrix Science, UK). Trypsin was chosen for cleav-
age with a maximum number of allowed missed cleavages
of two. Carbamidomethylation (C) and iTRAQ 4-plex la-
bels were set as fixed modifications. The searches were
performed using a peptide and product ion tolerance of
Zhang et al. Proteome Science  (2015) 13:12 Page 9 of 110.05 Da. Scaffold software was used to further filter the
database search results using the decoy database method
with the following filter: a 1% false-positive rate at the pro-
tein level and two unique peptides per protein. After filter-
ing the results as described above, the peptide abundances
in different reporter ion channels of the MS/MS scan were
normalized. The protein abundance ratio was based on
unique peptide results. Proteins with a fold change ≥ 2
were considered significantly altered.
Bioinformatics analysis
Data filtering was performed according to strict criteria,
wherein any missing data values or detection failures
were deleted. Pearson’s correlation coefficient was calcu-
lated to measure the quantitative correlation among the
three biological replicates in each group, and the coeffi-
cient of variation within groups was set at CV = 0.37 to
filter out low-quality data. A Student’s t-test was per-
formed between groups, and differences were considered
to be significant when p < 0.05. Any proteins that satis-
fied the criteria of a fold change (FC) between groups of
≥2 were selected for bioinformatics analysis using Gene
Ontology (GO) and Ingenuity Pathway Analysis (IPA).
GO functional and IPA network analysis
All proteins identified by the two approaches were
assigned a gene symbol using the Panther database
(http://www.pantherdb.org/). Protein classification was
performed based on the functional annotations of the
GO project for cellular compartment, molecular func-
tional and biological processed. When more than one as-
signment was available, all of the functional annotations
were considered in the results. Moreover, all of the se-
lected proteins with a significant fold changes were used
for pathway analysis using the IPA software (Ingenuity
Systems, Mountain View, CA) for network analysis.
Immunohistochemistry and western blot analysis
IHC was performed on the same six tissue samples used for
the proteomic analysis and on twelve additional formalin
fixed, paraffin embedded tissue samples. The following pri-
mary antibodies were used: anti-ELAVL1mouse monoclonal
(Santa Cruz), 1:500; anti-HNRNPK mouse monoclonal
(Santa Cruz), 1:50;anti-CDH2rabbit monoclonal (Cell Signal-
ing Technology), 1:250; anti-FBLN1 mouse monoclonal
(Santa Cruz),1:125; anti-CALU goat polyclonal (Santa Cruz),
1:100; anti-FGB goat polyclonal (Abcam), 1:16000. After
deparaffinization and rehydration, antigen retrieval was per-
formed by immersing the slide in antigenretrieval buffer
(10 mM sodium citrate, 0.05% Tween 20, pH= 6.0) at 95°C
for 5 min using pressure cooker. Endogenous peroxidases
were blocked with 0.03% hydrogen peroxide, and nonspecific
binding was blocked with 2% fetal calf serum in Tris-
buffered saline with 0.1% Triton X-100 (TBST, pH= 7.6).The sections were then incubated for 1 h at room
temperature with primary antibodies followed by peroxidase-
labeled polymer conjugate to anti-mouse, anti-rabbit,
anti-goat immunoglobulins for 1 h and developed with di-
aminobenzidine system. The sections were counter stained
with the Mayer’s hematoxylin and dehydrated, and the image
was taken under microscope.
WBs of the same six samples and additional twelve sam-
ples was performed to validate the proteomic quantitation
of four selected candidate proteins (HNRNPK, ELAVL1,
CDH2 and FBLN1). Proteins extracted from GBM or
PsPD tissues were resolved by SDS-PAGE (4–20% gradi-
ent precast gel; Invitrogen). The protein bands were elec-
tro transferred to a PVDF membrane (Millipore, Bedford,
MA), blocked with 2% (v/v) BSA in TBST (150 mM NaCl,
20 mM Tris, 0.1% Tween 20, pH = 7.4) for 2 h at room
temperature, followed by incubation with primary anti-
body (anti-ELAVL1, 1:200 (mouse monoclonal, Santa
Cruz); anti-HNRNPK,1:3000 (mouse monoclonal, Santa
Cruz); anti-CDH2, 1:800 (rabbit monoclonal, Cell Signal-
ing Technology); anti-FBLN1, 1:100, (mouse monoclonal,
Santa Cruz)) diluted with 1% BSA in TBST at room
temperature for 2 h. After extensive wash with TBST, the
membranes were incubated with horseradish peroxidase-
conjugated secondary antibody (anti-mouse or anti-rabbit;
EarthOX, USA) diluted with 1% BSA in TBST for 90 min
at room temperature. The membranes were developed
using Immobilon Western chemiluminescent horseradish
peroxidase substrate (Millipore). All the selected proteins
ELAVL1, HNRNPK, CDH2 and FBLN1 were validated by
Western blot analysis with actin as loading control.
Additional files
Additional file 1: File s1. Quantitative Peptide List for PsPD Samples.
Additional file 2: File s2. Quantitative Peptide List for N-GBM Samples.
Additional file 3: File s3. Quantitative Protein List for PsPD Samples.
Additional file 4: File s4. Quantitative Protein List for N-GBM Samples.
Additional file 5: Figure s1. Pearson correlation coefficient plot of
each two proteomic runs related to the tissue specimen in each group.
The three graphs in the first row of the figure refers to Pearson
coefficient of any two samples in PsPD sample group (ranged from 0.974
to 0.980); The three graphs in the second row of the figure refers to the
Pearson coefficient of any two samples in GBM sample group (ranged
from 0.967 to 0.978).
Additional file 6: File s5. Significantly Fold Changed Proteins between
PsPD and N-GBM Samples.
Additional file 7: File s6. Quantitative peptides of differentially
expressed proteins between PsPD and N-GBM samples.
Additional file 8: File s7. List of secreted proteins.
Additional file 9: Table S1. Parameters of ROC curve for four proteins.
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